Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer

Area of Science:

• Oncology
• Cancer Research
• Pharmacology

Background:

• Docetaxel is an effective chemotherapy for hormone refractory prostate cancer (HRPC).
• The development of novel combination therapies for HRPC is rapidly expanding.
• A need exists for efficient screening systems to evaluate these new treatments.

Purpose of the Study:

• To review the utility of xenograft models in selecting effective combination therapies for HRPC.
• To highlight the role of xenograft models in accelerating the translation of preclinical findings to clinical trials.

Main Methods:

• Review of existing literature on xenograft models in prostate cancer research.
• Analysis of studies employing xenograft models for combination therapy screening.
• Discussion of the advantages and limitations of xenograft models for HRPC drug development.

Main Results:

• Xenograft models provide a valuable platform for evaluating the efficacy of novel drug combinations in a preclinical setting.
• These models can help prioritize therapies with the highest likelihood of success in clinical trials.
• Successful application of xenograft models can expedite the identification of optimal treatment strategies for HRPC.

Conclusions:

• Xenograft models are crucial for the fast-track screening of combination therapies in hormone refractory prostate cancer.
• Utilizing xenograft models can significantly improve the efficiency of selecting promising treatments for phase II clinical trials, ultimately benefiting HRPC patients.